References
- TefferiAThieleJOraziAProposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panelBlood200711041092109717488875
- NimerSDMyelodysplastic syndromeBlood2008111104841485118467609
- SteensmaDPTefferiAThe myelodysplastic syndrome(s): a perspective and review highlighting current controversiesLeuk Res20032729512012526916
- Van EttenRAShannonKMFocus on myeloproliferative diseases and myelodysplastic syndromesCancer Cell20046654755215607959
- IssaJPBaylinSBHermanJGDNA methylation changes in hematologic malignancies: biologic and clinical implicationsLeukemia199711Suppl 1S7S119130685
- MelkiJRClarkSJDNA methylation changes in leukaemiaSemin Cancer Biol200212534735712191634
- BarosiGAmbrosettiAFinelliCThe Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid MetaplasiaBr J Haematol1999104473073710192432
- BarbuiTBarosiGBirgegardGPhiladelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNetJ Clin Oncol201129676177021205761
- ReillyJTMcMullinMFBeerPAGuideline for the diagnosis and management of myelofibrosisBr J Haematol2012158445347122651893
- ThomasDAGilesFJAlbitarMThalidomide therapy for myelofibrosis with myeloid metaplasiaCancer200610691974198416583431
- MesaRASteensmaDPPardananiAA phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasiaBlood200310172534254112517815
- NischalSBhattacharyyaSChristopeitMMethylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasmsCancer Res20137331076108523066032
- Quintas-CardamaATongWKantarjianHA phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosisLeukemia200822596597018385750
- AdèsLSekeresMAWolfrommAPredictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidineLeuk Res201337660961323415110
- OdenikeOMGodwinJEVan BesienKPhase II trial of low dose, subcutaneous decitabine in myelofibrosisPoster presented at: 50th ASH Annual Meeting and ExpositionDecember 6–9, 2008San Francisco, CA
- QinTYoussefEMJelinekJChenRYangASGarcia-ManeroGIssaJPEffect of cytarabine and decitabine in combination in human leukemic cell linesClin Cancer Res200713144225423217634552
- SaunthararajahYSekeresMAdvaniAEvaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromesJ Clin Invest201512531043105525621498